Select Bibliography

Filter by any of these (after searching):

CALGB-50303

AUTHOR ABSTRACT DEADLINES

A meeting abstract must be submitted by the first or corresponding author to the Alliance Publications Coordinator (publications@AllianceNCTN.org) at least two weeks prior to the meeting abstract submission deadline. For detailed information about Alliance Publications guidelines, please refer to the policies, along with the author abstract deadlines.

There are 9 items

Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303

Bartlett, Nancy L. , Wilson, Wyndham H. , Jung, Sin-Ho , Hsi, Eric D. ... - - J Clin Oncol - 2019

Manuscript - Primary - Primary - Lymphoma - CALGB-50303

Participation in cancer pharmacogenomic studies in 8,456 patients registered to Cancer and Leukemia Group B (Alliance) clinical trials

Dressler, L. G. , Deal, A. M. , Watson, D. , Hollis, D. , Owzar, K. ... - ASCO - J Clin Oncol - 2013

Abstract - Secondary-not-in-original - Meta-Analysis - Health Outcomes - CALGB-40101 , CALGB-50303 , CALGB-80203 , CALGB-80303 , CALGB-80405 , CALGB-90401

Participation in Cancer Pharmacogenomic Studies: A Study of 8456 Patients Registered to Clinical Trials in the Cancer and Leukemia Group B (Alliance)

Dressler, Lynn G. , Deal, Allison M. , Owzar, Kouros ... - - J Natl Cancer Inst - 2015

Manuscript - Secondary-not-in-original - Meta-Analysis - Health Outcomes - CALGB-40101 , CALGB-50303 , CALGB-80101 , CALGB-80203 , CALGB-80303 , CALGB-80405 , CALGB-90401

Association of CEP72 rs924607 with vincristine-induced peripheral neuropathy in patients with diffuse large B-cell lymphoma on Alliance/CALGB 50303

Hertz, Daniel L. , Larson, Nicholas , Pierpont, Timothy M ... - ASCO - J Clin Oncol - 2020

Abstract - Secondary-not-in-original - Primary - PPP - CALGB-50303

Development of a Conditional Event-Free Survival Tool in Diffuse Large B-Cell Lymphoma (Alliance)

Luan, Danny , Chen, Zhengming , Jakobsen, Lasse , Maurer, Matthew ... - ASH - Blood - 2022

Abstract - Primary - Primary - Lymphoma - A152112 , CALGB-50303 , E1412 , E4494 , S1001

Local Review versus (vs) Central Review of Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) in Diffuse Large B-Cell Lymphoma (DLBCL): Results from the CALGB 50303 Trial (Alliance)

Ruppert, Amy S. , Pederson, Levi D. , Knopp, Michael V. , Poon, David ... - ASH - Blood - 2020

Abstract - Secondary-not-in-original - Primary - Lymphoma - CALGB-50303

Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 clinical trial

Schöder, Heiko , Polley, Mei-Yin C. , Knopp, Michael V. ... - - Blood - 2020

Manuscript - Secondary - Primary - Lymphoma - CALGB-50303

Is local review of positron emission tomography scans sufficient in diffuse large B‐cell lymphoma clinical trials? A CALGB 50303 analysis

Torka, Pallawi , Pederson, Levi D. , Knopp, Michael V. , Poon, David ... - - Cancer Med - 2023

Manuscript - Secondary-not-in-original - Primary - Lymphoma - CALGB-50303

Phase III randomized study of R-CHOP versus DA-EPOCH-R and molecular analysis of untreated diffuse large B-cell lymphoma: Alliance/CALGB 50303

Wilson, Wyndham H. , Jung, Sin-Ho , Pitcher, Brandelyn , Hsi, Eric ... - ASH - Blood - 2016

Abstract - Primary - Primary - Lymphoma - CALGB-50303